August 14, 2014 – A new study reveals promising news for people suffering from mesothelioma. Researchers have identified an anti-mesothelin immunotoxin called SS1P that appears to increase the effectiveness of chemotherapy in fighting the disease. Chemotherapy is commonly used in treating mesothelioma, and the addition of SS1P could be a huge step in improving prognoses for mesothelioma patients.
The study was conducted by researchers at the National Cancer Institute’s Center for Cancer Research. Patients with advanced, inoperable mesothelioma were given SS1P in addition to standard chemotherapy. The researchers found that 77% of patients who were given the maximum tolerated dose of SSP1 had a partial response. Researchers concluded that SSP1 was not only safe and well tolerated by the patients, but also demonstrated anti-tumor activity.
Researchers are optimistic about the effect that this development could have on mesothelioma treatment. While chemotherapy is often the first method of treatment for patients, it can only go so far in combating the disease. The introduction of SS1P could make a difference for thousands of mesothelioma patients.
Pennsylvania Mesothelioma Attorneys at Shein Law Advocate for Asbestos Exposure Victims
The Philadelphia asbestos attorneys at Shein Law have been helping mesothelioma victims get justice for over 30 years. Our knowledgeable, professional legal team will review the facts of your case and ensure that you get the maximum settlement to which you are entitled. We understand this is a difficult time, and we will handle your case with compassion and care. With offices conveniently located in Philadelphia, PA, and Pennsauken, NJ, we serve clients throughout Pennsylvania and New Jersey. Call us toll-free at 1-877-SHEINLAW (743-4652) or contact us online for a free consultation with a qualified attorney.